IL-1β is reported to inhibit insulin signaling (92–94); randomized clinical trials shows that blocking IL-1β signaling (using recombinant human IL-1 receptor antagonist) is effective in type 2 diabetes (94). This evidence concerns the gene IL1B and type 2 diabetes mellitus.